Deutsche Bank analyst Glen Santangelo raised his price target for athenahealth to $160 and keeps a Hold rating on the shares. The stock currently trades at a fair level with balanced risk/reward in light of the $160 per share all-cash takeover bid from Elliott Management, Santangelo tells investors in a research note. The analyst continues to believe that "poor" end-market demand trends will persist and that athenahealth will need to identify additional growth levers beyond the core business to help accelerate sales. As such, he anticipates that shareholders will be supportive of a decision to accept Elliott's bid.